- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Early-stage venture capital firm OVP Venture Partners (OVP) today announced the addition of Carl Weissman as Venture Partner. Mr. Weissman will focus on investments in digital biology and the convergence of IT, nanotechnology, and biotechnology.
Mr. Weissman is currently the President & CEO of Accelerator, a Seattle-based joint investment vehicle for a syndicate of venture capital investors - including OVP - identifying, investing in, and managing emerging biotechnology opportunities. Under Mr. Weissman's direction, Accelerator has generated a number of drug development companies in which the engine for discovery of novel therapeutics is based upon digital biology.
"We are building on the success of our existing partnership to create even greater opportunities in this space," said OVP General Partner and Accelerator board member Chad Waite. "Carl has unique skills and experience in this field and we are excited to broaden and deepen our relationship with him and with Accelerator."
OVP and Accelerator first announced a partnership in November, 2004. The partnership has successfully incubated new ventures combining advanced information technologies with advanced biotechnology research. Since inception, Accelerator has invested $21.8M in six biotechnology start-ups. One of Accelerator's first graduates, Viral Logic Systems Technology (VLST), raised a $55M Series B round co-led by OVP in June, 2006.
Prior to Accelerator, Mr. Weissman was President and CEO of Centagenetix, where he led the February 2003 merger of Centagenetix with Elixir Pharmaceuticals, remaining on the Board of Directors of the combined entity until January, 2005.
Mr. Weissman will continue to serve as President & CEO of Accelerator.
For over 24 years, OVP Venture Partners has led the drive into new, high-growth technology markets in the Pacific Northwest. OVPís strategy of focusing on early-stage investments in defined spaces has yielded proven results; the firmís record of 51 liquidity events Ė including 22 IPOs Ė leads the region. The OVP team has a passion for working with ground-breaking entrepreneurs and high-caliber investors, and is known for its performance track record and personal integrity. OVP has over $700 million in capital under management and is currently investing its seventh fund.
OVP has offices in Seattle and Portland and concentrates its efforts on opportunities at the intersection of technologyís next big waves and foundational strengths native to the region. The firmís recent activity has included deals in communications, software, security, semiconductor, digital biology, and nanotechnology.
The OVP team includes investing partners Chad Waite, Lucinda Stewart, Rick LeFaivre and Carl Weissman in Seattle and Gerry Langeler, Dave Chen and John Hull in Portland. Chad Waite serves on the Board of the National Venture Capital Association (NVCA).
More information on the partnership is available at http://www.ovp.com .
For more information, please click here
OVP Venture Partners
Sara Morris, 206-851-5590
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEIís QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016
French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Regionís Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016